Xencor, Inc.

Healthcare · Biotechnology · United States

Last price 29.82 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.22B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase...